vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and GREAT SOUTHERN BANCORP, INC. (GSBC). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $56.4M, roughly 1.5× GREAT SOUTHERN BANCORP, INC.). GREAT SOUTHERN BANCORP, INC. runs the higher net margin — 28.9% vs 22.8%, a 6.1% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -0.2%). GREAT SOUTHERN BANCORP, INC. produced more free cash flow last quarter ($70.1M vs $28.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 4.5%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

FDMT vs GSBC — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.5× larger
FDMT
$85.1M
$56.4M
GSBC
Growing faster (revenue YoY)
FDMT
FDMT
+8508900.2% gap
FDMT
8508900.0%
-0.2%
GSBC
Higher net margin
GSBC
GSBC
6.1% more per $
GSBC
28.9%
22.8%
FDMT
More free cash flow
GSBC
GSBC
$41.6M more FCF
GSBC
$70.1M
$28.5M
FDMT
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
4.5%
GSBC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDMT
FDMT
GSBC
GSBC
Revenue
$85.1M
$56.4M
Net Profit
$19.4M
$16.3M
Gross Margin
Operating Margin
17.3%
34.5%
Net Margin
22.8%
28.9%
Revenue YoY
8508900.0%
-0.2%
Net Profit YoY
139.1%
9.1%
EPS (diluted)
$0.43
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
GSBC
GSBC
Q4 25
$85.1M
$56.4M
Q3 25
$90.0K
$57.8M
Q2 25
$15.0K
$59.2M
Q1 25
$14.0K
$55.9M
Q4 24
$1.0K
$56.5M
Q3 24
$3.0K
$55.0M
Q2 24
$5.0K
$56.7M
Q1 24
$28.0K
$51.6M
Net Profit
FDMT
FDMT
GSBC
GSBC
Q4 25
$19.4M
$16.3M
Q3 25
$-56.9M
$17.8M
Q2 25
$-54.7M
$19.8M
Q1 25
$-48.0M
$17.2M
Q4 24
$14.9M
Q3 24
$-43.8M
$16.5M
Q2 24
$-35.0M
$17.0M
Q1 24
$-32.4M
$13.4M
Operating Margin
FDMT
FDMT
GSBC
GSBC
Q4 25
17.3%
34.5%
Q3 25
-67983.3%
38.2%
Q2 25
-396373.3%
41.0%
Q1 25
-383007.1%
38.4%
Q4 24
31.8%
Q3 24
-1704400.0%
36.6%
Q2 24
-849120.0%
36.8%
Q1 24
-136200.0%
32.1%
Net Margin
FDMT
FDMT
GSBC
GSBC
Q4 25
22.8%
28.9%
Q3 25
-63195.6%
30.7%
Q2 25
-364386.7%
33.4%
Q1 25
-342657.1%
30.7%
Q4 24
26.4%
Q3 24
-1461433.3%
30.0%
Q2 24
-699060.0%
30.0%
Q1 24
-115717.9%
26.0%
EPS (diluted)
FDMT
FDMT
GSBC
GSBC
Q4 25
$0.43
$1.44
Q3 25
$-1.01
$1.56
Q2 25
$-0.98
$1.72
Q1 25
$-0.86
$1.47
Q4 24
$1.27
Q3 24
$-0.79
$1.41
Q2 24
$-0.63
$1.45
Q1 24
$-0.66
$1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
GSBC
GSBC
Cash + ST InvestmentsLiquidity on hand
$402.7M
$189.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$505.7M
$636.1M
Total Assets
$566.7M
$5.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
GSBC
GSBC
Q4 25
$402.7M
$189.6M
Q3 25
$305.1M
$196.2M
Q2 25
$293.2M
$245.9M
Q1 25
$321.4M
$217.2M
Q4 24
$424.9M
$195.8M
Q3 24
$501.9M
$208.4M
Q2 24
$541.9M
$186.5M
Q1 24
$525.9M
$171.4M
Stockholders' Equity
FDMT
FDMT
GSBC
GSBC
Q4 25
$505.7M
$636.1M
Q3 25
$369.0M
$632.9M
Q2 25
$420.9M
$622.4M
Q1 25
$469.7M
$613.3M
Q4 24
$510.6M
$599.6M
Q3 24
$552.9M
$612.1M
Q2 24
$588.3M
$568.8M
Q1 24
$600.6M
$565.2M
Total Assets
FDMT
FDMT
GSBC
GSBC
Q4 25
$566.7M
$5.6B
Q3 25
$424.0M
$5.7B
Q2 25
$473.6M
$5.9B
Q1 25
$515.7M
$6.0B
Q4 24
$560.4M
$6.0B
Q3 24
$604.0M
$6.0B
Q2 24
$620.1M
$6.0B
Q1 24
$629.9M
$5.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
GSBC
GSBC
Operating Cash FlowLast quarter
$28.6M
$81.5M
Free Cash FlowOCF − Capex
$28.5M
$70.1M
FCF MarginFCF / Revenue
33.5%
124.3%
Capex IntensityCapex / Revenue
0.1%
20.3%
Cash ConversionOCF / Net Profit
1.47×
5.01×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$121.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
GSBC
GSBC
Q4 25
$28.6M
$81.5M
Q3 25
$-46.5M
$5.6M
Q2 25
$-43.4M
$39.3M
Q1 25
$-47.8M
$15.0M
Q4 24
$-134.6M
$44.1M
Q3 24
$-29.4M
$17.7M
Q2 24
$-30.2M
$43.5M
Q1 24
$-29.1M
$-26.9M
Free Cash Flow
FDMT
FDMT
GSBC
GSBC
Q4 25
$28.5M
$70.1M
Q3 25
$-46.6M
$3.9M
Q2 25
$-43.4M
$34.9M
Q1 25
$-48.4M
$13.1M
Q4 24
$-138.4M
$39.1M
Q3 24
$-31.2M
$16.5M
Q2 24
$-30.6M
$42.0M
Q1 24
$-29.8M
$-27.7M
FCF Margin
FDMT
FDMT
GSBC
GSBC
Q4 25
33.5%
124.3%
Q3 25
-51765.6%
6.7%
Q2 25
-289620.0%
59.0%
Q1 25
-345635.7%
23.4%
Q4 24
-13837100.0%
69.3%
Q3 24
-1038966.7%
30.1%
Q2 24
-611840.0%
74.1%
Q1 24
-106421.4%
-53.7%
Capex Intensity
FDMT
FDMT
GSBC
GSBC
Q4 25
0.1%
20.3%
Q3 25
101.1%
3.0%
Q2 25
440.0%
7.4%
Q1 25
4507.1%
3.5%
Q4 24
378600.0%
8.7%
Q3 24
59266.7%
2.1%
Q2 24
6980.0%
2.7%
Q1 24
2535.7%
1.6%
Cash Conversion
FDMT
FDMT
GSBC
GSBC
Q4 25
1.47×
5.01×
Q3 25
0.31×
Q2 25
1.99×
Q1 25
0.87×
Q4 24
2.95×
Q3 24
1.07×
Q2 24
2.56×
Q1 24
-2.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons